Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics to present ATR 1072 nonclinical data at HCMS on November 6

Neutral Impact 2 of 5 other Written later

On November 2, 2026, Atrium Therapeutics announced a November 6 poster presentation at the Hypertrophic Cardiomyopathy Medical Society meeting, held during the American Heart Association Scientific Sessions 2026 in Chicago. The poster covers nonclinical results for lead candidate ATR 1072 in a new mouse model of PRKAG2 syndrome, where the company reports reversal of cardiac glycogen accumulation and improvement in hypertrophy and ECG parameters. The filing contains no financial results, and the company notes that nonclinical results may not predict human outcomes.

Key points

  • Poster presentation on November 6, 2026 at 5:30 p.m. CT, Presentation Number HCM32, Chicago
  • In mice, a single dose of mATR 1072 after three weeks of established disease reversed cardiac glycogen accumulation and improved hypertrophy and ECG parameters
  • Company expects initial proof-of-concept data from the Phase 1/2 Corventis trial in the second half of 2027

The filing

CompanyAtrium Therapeutics, Inc. (RNA)
Form8-K, current report
Filed with the SECNov 2, 2026, 6:47 AM ET
Accession number0001193125-26-442601

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.